Real-World study to map next steps after key lymphoma drug fails
NCT ID NCT07310186
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at what happens to people with diffuse large B-cell lymphoma (a common blood cancer) after treatment with polatuzumab vedotin stops working. Researchers will track 200 patients in China to see which salvage treatments are used and how well they work. The goal is to gather real-world data to help doctors make better treatment decisions in the future.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this study could help doctors choose better treatments for DLBCL patients after polatuzumab vedotin stops working.
- What could go wrong
- This is an observational study, not a test of a new treatment. It only collects data, so it won't directly improve outcomes for participants.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE-LARGE B-CELL LYMPHOMA (DLBCL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Drug combo keep aggressive lymphoma at bay?
- Can a 'Universal' cancer target outsmart resistant blood cancers?
- Can a single shot build a cancer army inside the body?
- Can a smart immune cell with a kill switch beat tough lymphomas?
- Ultra-Fast CAR-T cells aim to beat back tough lymphomas
- New drug combo aims to boost lymphoma treatment